Biotinylated Nipah virus Post-Fusion glycoprotein, His,Avitag™ (MALS verified)

Biotinylated Nipah virus Post-Fusion glycoprotein, His,Avitag™ (MALS verified)

• Background: Hendra virus (HeV) and Nipah virus (NiV) are henipaviruses discovered in the mid-to late 1990s that possess a broad host tropism and are known to cause severe and often fatal disease in both humans and animals. HeV and NiV infect host cells through the coordinated efforts of two envelope glycoproteins. The G glycoprotein attaches to cell receptors, triggering the fusion (F) glycoprotein to execute membrane fusion. G is a type II homotetrameric transmembrane protein responsible for binding to ephrinB2 or ephrinB3 (ephrinB2/B3) receptors. F is a homotrimeric type I transmembrane protein that is synthesized as a premature F0 precursor and cleaved by cathepsin L during endocytic recycling to yield the mature, disulfide-linked, F1 and F2 subunits. Upon binding to ephrinB2/B3, NiV G undergoes conformational changes leading to F triggering and insertion of the F hydrophobic fusion peptide into the target membrane. Subsequent refolding into the more stable post-fusion F conformation drives merger of the viral and host membranes to form a pore for genome delivery to the cell cytoplasm.
• Description: Biotinylated Nipah virus Post-Fusion glycoprotein, His,Avitag (PON-V82E3) is expressed from human 293 cells (HEK293). It contains AA Ile 27 - Asn 99 & Gly 117 - Ser 488 (Accession # Q9IH63-1).
• Specifications: This protein carries a polyhistidine tag at the C-terminus, followed by an Avi tag (Avitag™). The protein has a calculated MW of 56.2 kDa. The protein migrates as 58-63 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.
• Expression Region: Ile 27 - Asn 99 & Gly 117 - Ser 488
• Host: HEK 293
• Target: Postfusion glycoprotein F0/post-F protein (NiV)
• Conjugation: Biotin-labeled
• Tag: C-10×His & C-Avi
• Source: Nipah virus
• Stability: -20°C to -70°C for 12 months in lyophilized state; -70°C for 3 months under sterile conditions after reconstitution._x000D_For long term storage, the product should be stored at lyophilized state at -20°C or lower.
• Endotoxin: 1.0 EU per μg
• Purity: 90%
• Bioactivity: Immobilized Human Anti-Nipah-Post-F0,Human IgG1 | Human Kappa at 1 μg/mL (100 μL/well) can bind Biotinylated Nipah virus Post-Fusion glycoprotein, His,Avitag (Cat. No. PON-V82E3) with a linear range of 0.3-20 ng/mL (QC tested).
• Format: Powder
• Buffer: 0.1 M Sodium citrate, pH5.5
• Additives: Trehalose
• Molecular Weight: 56.2 kDa
• Shipping Conditions: Room Temperature
• Storage Conditions: -20°C